Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure
Introduction: Donor-specific antibodies (DSAs) are considered an important risk factor for graft injury and failure. However, there is limited information on long-term outcomes for kidney transplant recipients with positive DSAs in the absence of rejection on biopsy. Methods: We evaluated all patien...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-08-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024919301585 |
| _version_ | 1828898623614615552 |
|---|---|
| author | Sandesh Parajuli Emily Joachim Sayee Alagusundaramoorthy Fahad Aziz Justin Blazel Neetika Garg Brenda Muth Maha Mohamed Robert R. Redfield Didier A. Mandelbrot Weixiong Zhong Arjang Djamali |
| author_facet | Sandesh Parajuli Emily Joachim Sayee Alagusundaramoorthy Fahad Aziz Justin Blazel Neetika Garg Brenda Muth Maha Mohamed Robert R. Redfield Didier A. Mandelbrot Weixiong Zhong Arjang Djamali |
| author_sort | Sandesh Parajuli |
| collection | DOAJ |
| description | Introduction: Donor-specific antibodies (DSAs) are considered an important risk factor for graft injury and failure. However, there is limited information on long-term outcomes for kidney transplant recipients with positive DSAs in the absence of rejection on biopsy. Methods: We evaluated all patients at the University of Wisconsin who underwent a kidney allograft biopsy between January 1, 2013, and December 31, 2016. All patients with clinical indication or protocol biopsies that were negative for acute rejection and lacked significant acute pathological features were included in the study and divided into 2 groups based on DSAs at the time of biopsy. There were a total of 1102 kidney biopsies during the study period of which 587 fulfilled our selection criteria (DSA+, n = 192, and DSA−, n = 395). The incidence of subsequent rejection and death-censored graft failure (DCGF) were outcomes of interest. Results: There was no difference in acute (i + t + v + c4d + ptc + g = 0 in both groups) or chronic (ci + ct + cv + cg = 2.4 ± 2.2 vs. 2.7 ± 2.4; cg = 0.12 ± 0.48 vs. 0.13 ± 0.48) Banff scores in the index biopsy. Patients were followed for a mean of 33.1 ± 16.8 months. Kaplan-Meier analyses demonstrated a higher incidence of DCGF in DSA− group (n = 83) but this was not observed for subsequent rejection (n = 76). In multivariate Cox regression analyses, the interval from transplant to biopsy, de novo DSA, and younger age remained independently associated with increased risk of subsequent rejection. Notably, there was no association between subsequent rejection or DSA (pretransplant, de novo, persistant, Class I/II, MFIsum, or MFImax) and graft failure. Conclusion: This study suggests that in the absence of biopsy-proven rejection and acute inflammation, human leukocyte antigen (HLA) DSAs are not associated with increased risk of graft failure. Keywords: biopsies, DSA, graft survival, kidney transplant |
| first_indexed | 2024-12-13T15:18:39Z |
| format | Article |
| id | doaj.art-d2e0fe1e63314a878e547c4306adfb1a |
| institution | Directory Open Access Journal |
| issn | 2468-0249 |
| language | English |
| last_indexed | 2024-12-13T15:18:39Z |
| publishDate | 2019-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj.art-d2e0fe1e63314a878e547c4306adfb1a2022-12-21T23:40:38ZengElsevierKidney International Reports2468-02492019-08-014810571065Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft FailureSandesh Parajuli0Emily Joachim1Sayee Alagusundaramoorthy2Fahad Aziz3Justin Blazel4Neetika Garg5Brenda Muth6Maha Mohamed7Robert R. Redfield8Didier A. Mandelbrot9Weixiong Zhong10Arjang Djamali11Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Correspondence: Sandesh Parajuli, Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, UW Medical Foundation Centennial Building 4175, 1685 Highland Avenue, Madison, Wisconsin 53705, USA.Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADepartment of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USADivision of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USAIntroduction: Donor-specific antibodies (DSAs) are considered an important risk factor for graft injury and failure. However, there is limited information on long-term outcomes for kidney transplant recipients with positive DSAs in the absence of rejection on biopsy. Methods: We evaluated all patients at the University of Wisconsin who underwent a kidney allograft biopsy between January 1, 2013, and December 31, 2016. All patients with clinical indication or protocol biopsies that were negative for acute rejection and lacked significant acute pathological features were included in the study and divided into 2 groups based on DSAs at the time of biopsy. There were a total of 1102 kidney biopsies during the study period of which 587 fulfilled our selection criteria (DSA+, n = 192, and DSA−, n = 395). The incidence of subsequent rejection and death-censored graft failure (DCGF) were outcomes of interest. Results: There was no difference in acute (i + t + v + c4d + ptc + g = 0 in both groups) or chronic (ci + ct + cv + cg = 2.4 ± 2.2 vs. 2.7 ± 2.4; cg = 0.12 ± 0.48 vs. 0.13 ± 0.48) Banff scores in the index biopsy. Patients were followed for a mean of 33.1 ± 16.8 months. Kaplan-Meier analyses demonstrated a higher incidence of DCGF in DSA− group (n = 83) but this was not observed for subsequent rejection (n = 76). In multivariate Cox regression analyses, the interval from transplant to biopsy, de novo DSA, and younger age remained independently associated with increased risk of subsequent rejection. Notably, there was no association between subsequent rejection or DSA (pretransplant, de novo, persistant, Class I/II, MFIsum, or MFImax) and graft failure. Conclusion: This study suggests that in the absence of biopsy-proven rejection and acute inflammation, human leukocyte antigen (HLA) DSAs are not associated with increased risk of graft failure. Keywords: biopsies, DSA, graft survival, kidney transplanthttp://www.sciencedirect.com/science/article/pii/S2468024919301585 |
| spellingShingle | Sandesh Parajuli Emily Joachim Sayee Alagusundaramoorthy Fahad Aziz Justin Blazel Neetika Garg Brenda Muth Maha Mohamed Robert R. Redfield Didier A. Mandelbrot Weixiong Zhong Arjang Djamali Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure Kidney International Reports |
| title | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| title_full | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| title_fullStr | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| title_full_unstemmed | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| title_short | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| title_sort | donor specific antibodies in the absence of rejection are not a risk factor for allograft failure |
| url | http://www.sciencedirect.com/science/article/pii/S2468024919301585 |
| work_keys_str_mv | AT sandeshparajuli donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT emilyjoachim donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT sayeealagusundaramoorthy donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT fahadaziz donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT justinblazel donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT neetikagarg donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT brendamuth donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT mahamohamed donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT robertrredfield donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT didieramandelbrot donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT weixiongzhong donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure AT arjangdjamali donorspecificantibodiesintheabsenceofrejectionarenotariskfactorforallograftfailure |